Patent: 10,279,014

Summary for Patent: 10,279,014

Title:	Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppressive therapy
Abstract:	A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.6, CasX, or argonaute protein, which target at least one nucleotide sequence of the JCV genome.
Inventor(s):	Khalili; Kamel (Bala Cynwyd, PA), Malcolm; Thomas (Bedminster, NJ), Kohn; Kenneth I. (West Bloomfield, MI)
Assignee:	Excision BioTherapeutics, Inc. (Bedminster, unknown) Temple University of the Commonwealth System of Higher Education (Philadelphia, unknown)
Application Number:	15/864,309
Patent Claims:	see list of patent claims

Details for Patent 10,279,014

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2039-05-17
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2039-05-17
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	10/27/2003		2039-05-17